i2o Therapeutics
i2o Therapeutics, Inc. is focused on developing GLP-1 combinations for obesity and cardio-renal-metabolic diseases. They have a pipeline that includes long-acting GLP-1 receptor agonists, long-acting amylin DACRAs, long-acting PYY receptor agonists, and long-acting glucagon receptor agonists. The company is working on innovative therapies in the metabolic disease space, with new website and corporate news coming soon.
Industries
Nr. of Employees
small (1-50)
i2o Therapeutics
Products
Long-acting GLP-1 receptor agonists (2 assets)
Two long-acting peptide assets designed to activate the GLP-1 receptor with extended duration of action for metabolic disease indications.
Long-acting amylin DACRAs (2 assets)
Two long-acting amylin dual-agonist (DACRA) peptide assets intended for modulation of amylin receptor pathways in metabolic disease.
Long-acting PYY receptor agonist (1 asset)
A long-acting peptide asset targeting peptide YY (PYY) receptor pathways for potential use in metabolic disease treatment.
Long-acting glucagon receptor agonist (1 asset)
A long-acting peptide asset designed to activate the glucagon receptor with extended duration, intended for cardio-renal-metabolic disease applications.
Long-acting GLP-1 receptor agonists (2 assets)
Two long-acting peptide assets designed to activate the GLP-1 receptor with extended duration of action for metabolic disease indications.
Long-acting amylin DACRAs (2 assets)
Two long-acting amylin dual-agonist (DACRA) peptide assets intended for modulation of amylin receptor pathways in metabolic disease.
Long-acting PYY receptor agonist (1 asset)
A long-acting peptide asset targeting peptide YY (PYY) receptor pathways for potential use in metabolic disease treatment.
Long-acting glucagon receptor agonist (1 asset)
A long-acting peptide asset designed to activate the glucagon receptor with extended duration, intended for cardio-renal-metabolic disease applications.
Expertise Areas
- Peptide therapeutic development
- Metabolic and obesity therapeutics
- Combination therapy design
- Early-stage asset and portfolio management
Key Technologies
- Peptide therapeutics
- Extended half-life / long-acting modalities
- Receptor agonist modalities (GLP-1, amylin, PYY, glucagon)
- Combination therapeutic platforms